ArticleNeurochemical research2026
Resveratrol Improves Memory and Reduces Neuroinflammation in an MPS IIIB Mouse Model.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B) is a neurodegenerative lysosomal storage disorder characterized by cognitive decline, behavioral abnormalities, and neuroinflammation, for which no effective central nervous system (CNS)-targeted therapy currently exists. Increasing evidence indicates that inflammatory processes contribute substantially to disease progression. In this study, we evaluated the effects of resveratrol on behavioral outcomes and neuroinflammatory markers in an MPS IIIB mouse model, including both sexes. Behavioral analyses demonstrated anxiety-like behavior and memory impairment in MPS IIIB mice. Resveratrol treatment improved cognitive performance, reduced anxiety-related behavior, and normalized exploratory activity. Premature deaths occurred only in untreated MPS IIIB mice. Hematological and biochemical analyses revealed systemic inflammation, erythropoietic stress, metabolic dysregulation, and altered liver-associated parameters. Diseased mice exhibited leukocytosis, elevated pro-inflammatory immune cell populations, increased globulin concentrations, disturbed glucose and lipid metabolism, and sex-dependent alterations in liver and renal markers. Resveratrol partially normalized these abnormalities and reduced inflammatory and hematological disorders. Peripheral and central inflammatory responses were assessed by measurement of IL-1β, IL-6, and c-Fos levels. MPS IIIB mice displayed widespread neuroinflammation in the hippocampus, cortex, and amygdala, with pronounced sex- and region-dependent differences. Females exhibited stronger inflammatory changes in CA1, CA2, and retrosplenial cortical regions, whereas males showed predominant involvement of CA3, dentate gyrus, and motor cortical areas. Resveratrol reduced pro-inflammatory cytokine production and normalized neuronal hyperactivity, particularly in males. Overall, resveratrol modulated neuroinflammatory markers and improved selected behavioral outcomes in MPS IIIB mice, suggesting its potential to ameliorate CNS-related manifestations of Sanfilippo syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.